Dergiler / Southern Clinics of Istanbul Eurasia / 2020 / Cilt: 31 - Sayı: 1

Macular Electrophysiology After Intravitreal Dexamethasone Implant in Patients with Branch Retinal Vein Occlusion

Retinal Ven Tıkanıklığı Hastalarında İntraviteral Deksametazon İmplant Sonrası Multifokal Elektroretinogram Değişiklikleri

Sayfa
46–49
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

In this study, although a significant increase in visual acuity and a significant decrease in central macular thickness were observed in six months after Ozurdex in BRVO patients, no significant functional change was observed in mfERG.

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Objective: This study aims to investigate functional changes in the macula by multifocal electroretinography (mfERG) following intravitreal dexamethasone implant for the treatment of macular edema secondary to branch retinal vein occlusion (BRVO).
📊
Temel Bulgular & Veri:Methods: Forty-two patients treated with intravitreal dexamethasone implant (Ozurdex®, Allergan, Irvine, CA) for macular edema secondary to branch retinal vein occlusion (17 male, 25 female, mean age: 58.4±10.3 years) were included this study.
💡
Sonuç & Katkı:In this study, although a significant increase in visual acuity and a significant decrease in central macular thickness were observed in six months after Ozurdex in BRVO patients, no significant functional change was observed in mfERG.
🔬Tür:Araştırma Makalesi
📍Kapsam:Genişletilmiş Akademik Örneklem
⚙️Değişkenler:Alan Parametreleri

Özet

Objective: This study aims to investigate functional changes in the macula by multifocal electroretinography (mfERG) following intravitreal dexamethasone implant for the treatment of macular edema secondary to branch retinal vein occlusion (BRVO). Methods: Forty-two patients treated with intravitreal dexamethasone implant (Ozurdex®, Allergan, Irvine, CA) for macular edema secondary to branch retinal vein occlusion (17 male, 25 female, mean age: 58.4±10.3 years) were included this study. All patients had a detailed ophthalmological examination, including determination of best-corrected visual acuity, slitlamp examination, dilated fundus examination, optical coherence imaging of the macula and multifocal electroretinography. These examinations were performed in all cases before the intravitreal injection of dexamethasone implant, and the patients were followed with these modalities until six months after implantation. Results: The mfERG changes in rings and effected quadrants were not statistically significant (p>0.05). Implicit times in affected quadrants were 38.74±3.76 ms and 39.88±3.63 ms in preimplantation period and were measured as 38.08±2.66 ms, 38.57 ms in the post-implantation period. Although p wave implicit times in all rings and effected quadrants were relatively shorter, the difference was not statistically significant (p>0.05). Conclusion: Previous reports with first and third month results showed no significant change in mfERG findings in patients with BRVO in the short term. In this study, although a significant increase in visual acuity and a significant decrease in central macular thickness were observed in six months after Ozurdex in BRVO patients, no significant functional change was observed in mfERG.

Abstract

Amaç: Bu çalışmanın amacı retinal ven dal tıkanıklığında makula ödemi tedavisinde kullanılan intravitreal deksametazon implantın (Ozurdex ®, Allergan, Irvine, CA) multifokal elektroretinogram (mfERG) deki etkinliğini gözlemleyerek Ozurdex’in retinanın fonksiyonel yapısındaki etkinliğini incelemektir. Gereç ve Yöntem: Çalışmamıza Kasım 2013–Kasım 2014 tarihleri arasında retinal ven dal tıkanıklığı (RVDT) nedeniyle Ozurdex implant uyguladığımız 17’si erkek toplam 42 hasta dahil edildi. Bütün hastalara Ozurdex uygulaması öncesinde snellen eşeline göre düzeltilmiş en iyi görme keskinliği, biomikroskopik muayene, optik koherent tomografi ile makuler kalınlık ve mfERG ölçümleri yapıldı. Hastalar deksametazon implant öncesi ve sonrası altıncı ayda mf ERG testi uygulandı. Bulgular: Etkilenen kadranlarda ve ringlerde mfERG değişiklikleri istatsitiksel olarak anlamlı bulunmadı (p>0.05). RVDT nedeniyle etkilenen kadranda implisit zamanı implantasyon öncesi 38.74±3.76 ms iken implantasyon sonrası 38.08±2.66 ms, olarak ölçüldü. Tüm ringlerde ve etkilenen kadranlarda p dalgasının implisit zamanı kısalmış olsa da bu durum istatistiksel olarak anlamlı bulunmadı. Sonuç: Daha önce yapılan çalışmalarda Ozurdex sonrası birinci ve üçünvü aylarda mfERG de anlamlı fonksiyonel etki görülmediği raporlanmıştır. Bu çalışmada RVDT hastalarında Ozurdex sonrası altıncı ayda görme keskinliğinde anlamlı artış, santral makula kalınlığında anlamlı azalma görülmesine rağmen mfERG de anlamlı fonskiyonel değişiklik görülmediği sonucuna varıldı.

🔖

Bu Makaleye Atıf Yap

BULUT, M. N., ÇALLI, Ü., KIVRAK, U., BULUT, K., AKÇAY, G. (2020). Macular Electrophysiology After Intravitreal Dexamethasone Implant in Patients with Branch Retinal Vein Occlusion. Southern Clinics of Istanbul Eurasia, Cilt: 31 - Sayı: 1, 46–49. https://ajindex.com/articles/313968

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (15)

  1. Branch Vein Occlusion Study Group. Argon Laser Photocoagulation For Macular Edema In Branch Vein Occlusion. Am J Ophthalmol 2018;196:30–8
  2. Zhao J, Sastry SM, Sperduto RD, Chew EY, Remaley NA. Arteriovenous crossing patterns in branch retinal vein occlusion. The Eye Disease Case-Control Study Group. Ophthalmology 1993;100:423–8
  3. Staurenghi G, Lonati C, Aschero M, Orzalesi N. Arteriovenous crossing as a risk factorin branch retinal vein occlusion. Am J Ophthalmol 1994;117:211–3
  4. Feist RM, Ticho BH, Shapiro MJ, Farber M. Branch retinal vein occlusion andquadratic variation in arteriovenous crossings. Am J Ophthalmol 1992;113:664–8
  5. Rehak M, Wiedemann P. Retinal vein thrombosis: pathogenesisand management. J Thromb Haemost 2010;8:1886–94
  6. Rehak J, Rehak M. Branch retinal vein occlusion: pathogenesis,visual prognosis, and treatment modalities. Curr Eye Res 2008;33:111–31
  7. Mohamed Q, McIntosh RL, Saw SM, Wong TY. Interventions for central retinal vein occlusion: an evidence-based systematic review. Ophthalmology 2007;114:507–19
  8. Mitchell P, Smith W, Chang A. Prevalence and associations of retinal vein occlusion in Australia: the Blue Mountains Eye Study. Arch Ophthalmol 1996;114:1243–7
  9. Klein R, Klein BE, Moss SE, Meuer SM. The epidemiology of retinal vein occlusion: the Beaver Dam Eye Study. Trans Am Ophthalmol Soc 2000;98:133–41
  10. Central Vein Occlusion Study Group. Natural history and clinical management of central retinal vein occlusion. Arch Ophthalmol 1997;115:486–91
  11. Haller JA, Bandello F, Belfort R Jr, Blumenkranz MS, Gillies M, Heier J, et al. Dexamethasone intravitreal implant in patients with macular edema related to branch or central retinal vein occlusion twelve-month study results. Ophthalmology 2011;118:2453–60
  12. Haller JA, Bandello F, Belfort R Jr, Blumenkranz MS, Gillies M, Heier J, et al. Randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with macular edema due to retinal vein occlusion. Ophthalmology 2010;117:1134–46.e3
  13. Fortune B, Schneck ME, Adams AJ. Multifocal electro-retinogram delays reveal local retinal dysfunction in early diabetic retinopathy. Invest Ophthalmol Vis Sci 1999;40:2638–51
  14. Sutter EE, Tran D. The field topography of ERG components in man-I. The photopic luminance response. Vision Res 1992;32:433– 46
  15. Hood DC, Frishman LJ, Saszik S, Viswanathan S. Retinal origins of the primate multifocal ERG: implications for the human response. Invest Ophtha